利拉鲁肽注射剂的仿制药获批将有助于增加患者获得 2 型糖尿病治疗的机会。利拉鲁肽注射剂目前处于短缺状态。 美国食品药品管理局（FDA）批准了首个仿制药Victoza（利拉鲁肽注射液）18毫克/3毫升，这是一种胰高血糖素样肽-1（GLP-1）受体激动剂 ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Check the Victoza medication guide for a full list of potential side effects. Trulicity is a GLP-1 agonist that helps manage type 2 diabetes and has shown to aid in weight loss. Clinical trials ...

Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...

GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza, Wegovy started as a way to treat diabetes but have since become popular for weight loss.